MEFLOQUINE HYDROCHLORIDE (mefloquine hydrochloride) by Medica Corp is clinical pharmacology pharmacokinetics absorption: the absolute oral bioavailability of mefloquine has not been determined since an intravenous formulation is not available. Approved for mild to moderate acute malaria caused by mefloquine-susceptible strains of p. First approved in 1989.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
Mefloquine hydrochloride is an oral antimalarial agent approved in 1989 for treatment of mild to moderate acute malaria caused by mefloquine-susceptible Plasmodium strains. It acts as a blood schizonticide with activity against erythrocytic stages of malaria parasites, including chloroquine-resistant strains. The drug undergoes extensive hepatic metabolism via CYP3A4 with a 3-week average elimination half-life.
Product approaching loss of exclusivity with minimal linked job activity indicates shrinking brand team and reduced commercial investment.
CLINICAL PHARMACOLOGY Pharmacokinetics Absorption: The absolute oral bioavailability of mefloquine has not been determined since an intravenous formulation is not available. The bioavailability of the tablet formation compared with an oral solution was over 85%. The presence of food significantly…
Worked on MEFLOQUINE HYDROCHLORIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on mefloquine offers limited career growth given LOE status and minimal linked job opportunities (0 identified). Roles would focus on defending market share against generics and managing legacy product commercialization rather than innovation or expansion.